IAR Systems Group AB (publ) (IARGF)

CTI BioPharma Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	85.3	135.2	-229	57.8	-67.4	59.4
Depreciation & Amortization	24.7	26.3	28.2	32.9	23.4	23.3
Other Amortization	29	29	28.8	20.3	30.9	25.6
Other Operating Activities	-12.6	-55.1	316.1	16.7	144.7	10.1
Operating Cash Flow	126.4	135.4	144.1	127.7	131.6	118.4
Operating Cash Flow Growth	-16.13%	-6.04%	12.84%	-2.96%	11.15%	12.02%
Capital Expenditures	-3.1	-3	-5.8	-9.3	-9.9	-3.2
Sale (Purchase) of Intangibles	-53.9	-51.5	-36.3	-50.2	-64.2	-78.2
Investment in Securities	-	-	0.3	-	-	-
Investing Cash Flow	-57	-54.5	-41.8	-59.5	-74.1	-81.4
Short-Term Debt Issued	-	-	-	-	0.9	5.5
Total Debt Issued	-	-	-	-	0.9	5.5
Short-Term Debt Repaid	-	-	-	-18	-	-13
Long-Term Debt Repaid	-	-18.8	-19.1	-21.6	-16.2	-17.2
Total Debt Repaid	-19	-18.8	-19.1	-39.6	-16.2	-30.2
Net Debt Issued (Repaid)	-19	-18.8	-19.1	-39.6	-15.3	-24.7
Issuance of Common Stock	-	-	-	0.1	0.2	0.1
Repurchase of Common Stock	-90.3	-86.6	-9.6	-	-	-
Common Dividends Paid	-20	-20	-20.5	-	-	-
Financing Cash Flow	-129.3	-125.4	-49.2	-39.5	-15.1	-24.6
Foreign Exchange Rate Adjustments	-3.8	2.5	-3.9	6.1	3.2	-5.3
Net Cash Flow	-63.7	-42	49.2	34.8	45.6	7.1
Free Cash Flow	123.3	132.4	138.3	118.4	121.7	115.2
Free Cash Flow Growth	-15.08%	-4.27%	16.81%	-2.71%	5.64%	11.63%
Free Cash Flow Margin	22.70%	24.68%	27.98%	25.19%	28.96%	30.97%
Free Cash Flow Per Share	9.19	9.77	10.17	8.61	8.92	8.44
Cash Interest Paid	2.5	2.7	2.6	1.7	1.6	1.8
Cash Income Tax Paid	43.1	34.6	11.2	16	3.6	7.9
Levered Free Cash Flow	45.94	61.51	84.14	52.54	51.35	15.9
Unlevered Free Cash Flow	48.19	63.08	84.64	53.6	52.35	17.03
Change in Net Working Capital	30.1	23.5	-10	-13.2	-42.4	13.6

Source: S&P Global Market Intelligence. Standard template. Financial Sources.